Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621007 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL14715897 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL12462787 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL14715877 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL14716003 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2158513 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2158518 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL14715931 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL2158527 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 | |
| SCHEMBL14715932 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | claimed |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-02-28 | — | — | US | claimed |
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670487-B2 | Cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-02-28 | — | — | US | disclosed |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-02-28 | — | — | US | disclosed |
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | BANK OF AMERICA, N.A. | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053572-A1 | Novel Cationic Lipids for Oligonucleotide Delivery | NPC1L1, CETP, LIPA | ALDH1A1 1441/4885CNR1 2652/4885CNR2 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.